Phase i safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211

S. Z. Usmani, R. Sexton, Sikander Ailawadhi, J. J. Shah, J. Valent, M. Rosenzweig, B. Lipe, J. A. Zonder, S. Fredette, B. Durie, A. Hoering, B. Bartlett, R. Z. Orlowski

Research output: Contribution to journalLetter

22 Citations (Scopus)
Original languageEnglish (US)
Article numbere334
JournalBlood Cancer Journal
Volume5
DOIs
StatePublished - Aug 7 2015

Fingerprint

Antineoplastic Combined Chemotherapy Protocols
Antibodies, Monoclonal, Humanized
Induction Chemotherapy
Thalidomide
Multiple Myeloma
Dexamethasone
Safety
Therapeutics
lenalidomide
Bortezomib
elotuzumab

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Phase i safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma : SWOG S1211. / Usmani, S. Z.; Sexton, R.; Ailawadhi, Sikander; Shah, J. J.; Valent, J.; Rosenzweig, M.; Lipe, B.; Zonder, J. A.; Fredette, S.; Durie, B.; Hoering, A.; Bartlett, B.; Orlowski, R. Z.

In: Blood Cancer Journal, Vol. 5, e334, 07.08.2015.

Research output: Contribution to journalLetter

Usmani, SZ, Sexton, R, Ailawadhi, S, Shah, JJ, Valent, J, Rosenzweig, M, Lipe, B, Zonder, JA, Fredette, S, Durie, B, Hoering, A, Bartlett, B & Orlowski, RZ 2015, 'Phase i safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211', Blood Cancer Journal, vol. 5, e334. https://doi.org/10.1038/bcj.2015.63
Usmani, S. Z. ; Sexton, R. ; Ailawadhi, Sikander ; Shah, J. J. ; Valent, J. ; Rosenzweig, M. ; Lipe, B. ; Zonder, J. A. ; Fredette, S. ; Durie, B. ; Hoering, A. ; Bartlett, B. ; Orlowski, R. Z. / Phase i safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma : SWOG S1211. In: Blood Cancer Journal. 2015 ; Vol. 5.
@article{9bc668131ad84fd093c577ee2f27140f,
title = "Phase i safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211",
author = "Usmani, {S. Z.} and R. Sexton and Sikander Ailawadhi and Shah, {J. J.} and J. Valent and M. Rosenzweig and B. Lipe and Zonder, {J. A.} and S. Fredette and B. Durie and A. Hoering and B. Bartlett and Orlowski, {R. Z.}",
year = "2015",
month = "8",
day = "7",
doi = "10.1038/bcj.2015.63",
language = "English (US)",
volume = "5",
journal = "Blood Cancer Journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Phase i safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma

T2 - SWOG S1211

AU - Usmani, S. Z.

AU - Sexton, R.

AU - Ailawadhi, Sikander

AU - Shah, J. J.

AU - Valent, J.

AU - Rosenzweig, M.

AU - Lipe, B.

AU - Zonder, J. A.

AU - Fredette, S.

AU - Durie, B.

AU - Hoering, A.

AU - Bartlett, B.

AU - Orlowski, R. Z.

PY - 2015/8/7

Y1 - 2015/8/7

UR - http://www.scopus.com/inward/record.url?scp=84938877642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938877642&partnerID=8YFLogxK

U2 - 10.1038/bcj.2015.63

DO - 10.1038/bcj.2015.63

M3 - Letter

C2 - 26252787

AN - SCOPUS:84938877642

VL - 5

JO - Blood Cancer Journal

JF - Blood Cancer Journal

SN - 2044-5385

M1 - e334

ER -